BioinvestGPT

BioinvestGPT ApS · Research use only

NCT04560998 (Semaglutide in type 2 diabetes and peripheral artery…): BVCT ex-ante prediction vs. reported outcome

On 24 Mar 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 29 Mar 2025 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT04560998
Acronym
STRIDE
Drug Name
Semaglutide
Drug MoA
GLP1R agonist
Drug Modality
peptide
Drug Class
First-In-Class
Therapeutic Area
Cardiovascular Diseases
Indication
type 2 diabetes and peripheral artery disease
Human Patients
792
Sponsor
Novo Nordisk
Phase
Phase 3

Prediction of , index 1531

Prospective Prediction
Prediction Index
1531
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient additive clinical benefit)
Technical Prediction
SUCCESS (statistically significant additive clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
370 days in advance
Readout Data Interpretation
semaglutide achieved a 13% placebo-adjusted improvement in maximum walking distance (p=0.0004) and 39.9 meter step incline walking distance improvement at week 52
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease
Phase
Phase 3
Status
Completed
Enrollment
792
Lead sponsor
Novo Nordisk A/S
Conditions
Diabetes Mellitus, Type 2; Peripheral Arterial Disease
Interventions
DRUG: Semaglutide; DRUG: Placebo (semaglutide)
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2020-10-01
Primary completion
2024-06-05
Completion
2024-07-12
Results first posted
2025-07-08
Primary outcomes
  • Change in Maximum Walking Distance on a Constant Load Treadmill Test (Baseline (week 0), end of treatment (week 52))

NCT04560998 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials